LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Stock List・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Open

SectorHealthcare

1.99 2.58

Buy Sell

Overview

Share price change

24h

Current

Min

1.99

Max

2.01

Key metrics
By Trading Economics
Income	-3.8M -43M
EPS	-0.18
Employees	150
EBITDA	-3.9M -43M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+335.5% upside

Dividends
By Dow Jones
Next Earnings	12 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-117M 670M
Previous open	-0.59
Previous close	1.99

News Sentiment

By Acuity

50%

151 / 345 Healthcare

Allogene Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 May 2026, 23:46 UTC

Market Talk

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 May 2026, 23:45 UTC

Market Talk

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 May 2026, 23:42 UTC

Market Talk

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 May 2026, 23:34 UTC

Market Talk

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 May 2026, 23:11 UTC

Market Talk

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 May 2026, 22:26 UTC

Acquisitions, Mergers, Takeovers

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 May 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 May 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 May 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 May 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 May 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 May 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 May 2026, 22:11 UTC

Market Talk

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 May 2026, 22:04 UTC

Market Talk

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 May 2026, 08:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

23 May 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 May 2026, 21:10 UTC

Earnings

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 May 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 May 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

22 May 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 May 2026, 19:47 UTC

Earnings

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 May 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 May 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 May 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22 May 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 May 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 May 2026, 18:35 UTC

Acquisitions, Mergers, Takeovers

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 May 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 May 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Peer Comparison

Price change

Allogene Therapeutics Inc Forecast

Price Target

By TipRanks

335.5% upside

12 Months Forecast

Average 8.71 USD 335.5%

High 14 USD

Low 3.85 USD

Based on 14 Wall Street analysts offering 12 month price targets forAllogene Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to Allogene Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

151 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.